Abstract
Erythrodermic atopic dermatitis (E-AD; ≥90% body surface area [BSA] affected and baseline [BL] erythema score ≥1 from Global Individual Signs Score) is often difficult to treat and highly disturbs patient (pt) physical/mental health. We report pooled efficacy data from dupilumab (DPL) monotherapy trials in adult and adolescent pts with E-AD. In 16-week DPL trials, 136 adults and adolescents with E-AD received DPL 300mg weekly (qw; n=38); DPL 200mg (adolescents: BL weight <60kg) or 300mg (adolescents: BL weight ≥60kg; and adults) every 2 weeks (q2w; n=48); or placebo (PBO; n=50).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
